The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.50
Bid: 9.30
Ask: 9.50
Change: -0.35 (-3.59%)
Spread: 0.20 (2.151%)
Open: 9.55
High: 10.00
Low: 9.50
Prev. Close: 9.75
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Mar 2015 14:22

RNS Number : 8081G
e-Therapeutics plc
06 March 2015
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

e-Therapeutics plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation:

Henderson Global Investors

4. Full name of shareholder(s) (if different from 3.):

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: 

5 March 2015

6. Date on which issuer notified:

6 March 2015

7. Threshold(s) that is/are crossed orreached:

Above 10%

     
 

 

8. Notified details:

A: Voting rights attached to shares 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct 

Indirect 

Direct

Indirect

Ordinary

17,539,408

17,539,408

 

 

 

26,640,299

 

 

 

 

10.07%

GB00B2823H99

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate 

Exercise/Conversion Period 

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments 

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date

Exercise/Conversion period

Number of voting rights instrument refers to

 

% of voting rights 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

26,640,299

10.07%

                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will ceaseto hold:

 

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

 

This disclosure has been calculated based on issue share capital amount 264,362,821.

 

14. Contact name:

Scott Dickenson

15. Contact telephone number:

020 7818 4184

   

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEALDKEFPSEFF
Date   Source Headline
21st Oct 20209:06 amRNSIssue of Equity
12th Oct 20203:15 pmRNSHolding(s) in Company
12th Oct 20207:00 amRNSAppointment of Ali Mortazavi as CEO
12th Oct 20207:00 amRNSInterim Results for six months ended 31 July 2020
5th Oct 202012:07 pmRNSNotice of Interim Results
28th Sep 20207:00 amRNSExpansion of Scientific Advisory Board
28th Jul 20205:46 pmRNSHolding(s) in Company
23rd Jul 202010:03 amRNSHolding(s) in Company
16th Jul 20205:55 pmRNSHolding(s) in Company
16th Jul 20205:55 pmRNSHolding(s) in Company
16th Jul 20207:01 amRNSHolding(s) in Company
16th Jul 20207:00 amRNSDirector/PDMR Shareholding
15th Jul 20207:00 amRNSDirector/PDMR Shareholding
14th Jul 20204:49 pmRNSExercise of Broker Option and Total Fundraise
9th Jul 20204:47 pmRNSExercise of Broker Option
8th Jul 20204:41 pmRNSSecond Price Monitoring Extn
8th Jul 20204:36 pmRNSPrice Monitoring Extension
8th Jul 20202:05 pmRNSSecond Price Monitoring Extn
8th Jul 20202:00 pmRNSPrice Monitoring Extension
8th Jul 20207:00 amRNSResult of Retail Offer
7th Jul 20205:46 pmRNSRetail Offer
7th Jul 20205:42 pmRNSFundraise of up to £12.4 million
22nd Jun 20207:00 amRNSHolding(s) in Company
10th Jun 20207:00 amRNSCollaboration with Galapagos
3rd Jun 20205:52 pmRNSHolding(s) in Company
2nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:36 pmRNSPrice Monitoring Extension
2nd Jun 20202:30 pmRNSResults of 2020 Annual General Meeting
28th May 20207:04 amRNSExpansion into RNAi and creation of SAB
18th May 20204:41 pmRNSSecond Price Monitoring Extn
18th May 20204:37 pmRNSPrice Monitoring Extension
18th May 202011:05 amRNSSecond Price Monitoring Extn
18th May 202011:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSExperimental testing initiated with WuXi AppTec
15th May 20205:17 pmRNSAnnual General Meeting – Change of Arrangement
15th May 20203:12 pmRNSe-therapeutics to present at Shares Evening
16th Apr 20202:05 pmRNSSecond Price Monitoring Extn
16th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 202011:05 amRNSSecond Price Monitoring Extn
16th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSAppointment of Chief Business Officer
23rd Mar 20207:00 amRNSAnti-viral drug discovery initiative
17th Mar 20207:00 amRNSResults for the year ended 31 January 2020
11th Mar 20201:30 pmRNSNotification of Full Year Results Date
20th Feb 20206:09 pmRNSHolding(s) in Company
18th Feb 202012:02 pmRNSHolding(s) in Company
11th Feb 202010:00 amRNSDirector/PDMR Shareholding
11th Feb 20207:00 amRNSBoard Changes and Placing
13th Jan 202012:58 pmRNSCorrection - Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.